Research Tracker›Biomarker Atlas›Hypertension›Asymmetric Dimethylarginine (ADMA)

Asymmetric Dimethylarginine (ADMA) in Hypertension

Asymmetric Dimethylarginine (ADMA) belongs to the other group of Hypertension markers, but reports against normotension group point in different directions. Symptom domains tied to this marker in the source include disaster-related hypertension after Great East Japan Earthquake. The evidence summarised here comes from Shiraishi et al. 2016 and reflects averages across cohorts rather than any single patient's result.

↕ InconsistentOtherLOINC 10988-1

Summary

Direction in Hypertension↕ Inconsistent — reported as both higher and lower across studies, with no consistent direction
CategoryOther
Compared againstnormotension group
Associated symptomsdisaster-related hypertension after Great East Japan Earthquake
Test typeBlood test (serum / plasma / whole blood)
LOINC code10988-1
SourceShiraishi et al. 2016 — doi:10.1536/ihj.15-303
Condition atlasHypertension Biomarker Atlas

Other conditions where Asymmetric Dimethylarginine (ADMA) is reported

See the cross-condition hub: Asymmetric Dimethylarginine (ADMA) across conditions.

Related Other markers in Hypertension

Full list: Hypertension Biomarker Atlas.

Frequently asked questions

Is Asymmetric Dimethylarginine (ADMA) high or low in Hypertension?

Mixed. Some studies report higher and others lower Asymmetric Dimethylarginine (ADMA) in Hypertension compared with normotension group, so no single direction is established. Source: Shiraishi et al. 2016.

What symptoms is Asymmetric Dimethylarginine (ADMA) associated with in Hypertension?

The cited literature associates this marker with disaster-related hypertension after Great East Japan Earthquake. These are population-level associations and do not mean the marker causes the symptoms.

Which test measures Asymmetric Dimethylarginine (ADMA)?

It is measured as a blood test (serum / plasma / whole blood). The standard laboratory code is LOINC 10988-1. Many of the cited studies used research-grade assays, so clinical availability may vary.

Is one abnormal Asymmetric Dimethylarginine (ADMA) result diagnostic of Hypertension?

No. No single biomarker is diagnostic of Hypertension. Asymmetric Dimethylarginine (ADMA) findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Is Asymmetric Dimethylarginine (ADMA) specific to Hypertension?

No. The same marker is also reported in Long COVID in this atlas, so it reflects shared biology (for example inflammation or vascular stress) rather than a condition-specific signature.

Cite this page

Open Source Medicine Foundation. (2026). Asymmetric Dimethylarginine (ADMA) in Hypertension: direction, evidence and what it means. OSMF Research Tracker. Retrieved October 8, 2026, from https://research.opensourcemed.info/biomarkers/hypertension/asymmetric-dimethylarginine-adma.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-10-08 · Page generated from hypertension.json · Browse: Hypertension atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.